SCHEMBL29759490

SCHEMBL29759490

Cc1ncc(NC(=O)CN2CCC3(CCC3)C2)cc1NC(=O)c1cnn2cc(-c3cnn(CCO)c3)sc12

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ WNT1 P04628 2/20 0.33
▸ GSK3B P49841 2/20 0.33
▸ DYRK1A Q13627 2/20 0.33
▸ IKBKE Q14164 1/20 0.33
▸ TBK1 Q9UHD2 1/20 0.33
▸ KCNH2 Q12809 2/20 0.32
▸ HDAC1 Q13547 2/20 0.32
▸ DRD3 P35462 1/20 0.32
▸ TMEM97 Q5BJF2 1/20 0.32
▸ SIGMAR1 Q99720 1/20 0.32
▸ MET P08581 1/20 0.32
▸ AXL P30530 1/20 0.32
▸ OGA O60502 3/20 0.31
▸ CSF1R P07333 1/20 0.30
▸ KIT P10721 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24577024 1.00 CHRM1 (0.35) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL24576875 0.97 WNT1 (0.35) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL29759480 0.97 WNT1 (0.35) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL29759509 0.93 GSK3B (0.39) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL24578175 0.93 GSK3B (0.39) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL24576881 0.92 CHRM1 (0.36) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL29759445 0.92 CHRM1 (0.36) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL24577746 0.91 IKBKE (0.37) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL29760006 0.91 IKBKE (0.37) CHRM1PDGFRAHRH3WNT1GSK3B
SCHEMBL24577926 0.90 IKBKE (0.36) CHRM1PDGFRAHRH3WNT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP claimed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO claimed
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 CHRM1 4399/4885PDGFRA 1/4885HRH3 1593/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback